China
Africa
Explore chapters and articles related to this topic
Atopic eczema
Published in Samar Razaq, Difficult Cases in Primary Care, 2021
Which of the following statements regarding eczema herpeticum are false? Most cases of eczema herpeticum are caused by herpes zoster virus.Recurrent episodes of eczema herpeticum are uncommon.All children should be treated with intravenous antiviral treatment.Antibiotic treatment is usually required to treat bacterial super-infection.Untreated, eczema herpeticum is potentially fatal.
Skin
Published in A. Sahib El-Radhi, Paediatric Symptom and Sign Sorter, 2019
Eczema herpeticum is a serious infection caused by herpes simplex virus, which is invading eczematous lesions. It can lead to death through dissemination of the virus to the brain and other organs or from secondary staphylococcal or streptococcal infection.
Skin
Published in A Sahib El-Radhi, James Carroll, Paediatric Symptom Sorter, 2017
A Sahib El-Radhi, James Carroll
Eczema herpeticum is a serious infection caused by herpes simplex virus that is invading eczematous lesions. It can lead to death through dissemination of the virus to the brain and other organs or from secondary staphylococcal or streptococcal infection.
Dupilumab for the treatment of adolescents with atopic dermatitis
Published in Expert Review of Clinical Immunology, 2020
Sonja Senner, Marlene Seegräber, Surina Frey, Benjamin Kendziora, Laurie Eicher, Andreas Wollenberg
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease of childhood in developed countries, where up to 30% of children are affected [1–5]. The disease begins in more than 85% of cases during early childhood. While AD is outgrown or considerably improving in around 50% of children by the age of seven, most of the children being affected during adolescence will also suffer from the disease in adulthood [6]. The highly pruritic and often stigmatizing skin lesions may lead to sleep deprivation, poor school performance, low self-esteem, and familial stress. The risk of developing psychiatric comorbidities, such as depression and anxiety disorders, is significantly increased in patients being severely affected by AD [7]. Skin colonization with Staphylococcus aureus increases the risk of invasive infections in children with moderate to severe AD, including endocarditis, infectious arthritis, and osteomyelitis. Disseminated viral infections are a diagnostic hallmark and clinically relevant complication of AD [8]. Eczema herpeticum, most commonly induced by herpes simplex virus 1, may lead to hepatitis and encephalitis [9]. The effective treatment of AD in children is of high importance, not only for improving the quality of life in affected children, but also for reducing the long-term costs to the health care system.
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Published in Journal of Dermatological Treatment, 2023
Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin-Weller, Diamant Thaçi, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth, Jacob P. Thyssen
The IRs for herpes simplex in the extended dataset (2 mg, 7.5 and 4 mg, 10.7) and All-bari dataset (6.7) were decreased from the previous report (All-bari IR 10.3 [7]). The majority (94%) were mild or moderate in severity and the most common preferred terms were oral herpes (n = 140), herpes simplex (n = 120), and eczema herpeticum (n = 67) (Supplemental Table 3). Two events of eczema herpeticum led to permanent discontinuation and 27 events led to temporary interruption of study drug. Of 67 patients who reported eczema herpeticum or Kaposi’s varicelliform eruption, a majority (64.2%) had poor disease control prior to the event (vIGA-AD scores of 3 or 4).
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review
Published in Expert Review of Clinical Pharmacology, 2023
Aishwarya Muddebihal, Ananta Khurana, Kabir Sardana
A meta-analysis of six RCTs and two long-term extension studies (total n = 2531) reported the pooled safety data of baricitinib in AD. Most of the reported AEs were mild and included upper respiratory tract infections and herpes simplex virus infections (higher with baricitinib 4 mg). Eczema herpeticum, cellulitis and pneumonia were the commonest serious side effects reported. Only two major adverse cardiovascular events and three thromboembolic events were reported in baricitinib group overall highlighting a good safety profile [46].